In spring 2015, SEKISUI Diagnostics and the global healthcare company Abbott made an agreement to offer coagulation testing solutions for laboratories worldwide.
Coagulation tests measure a person’s blood clotting ability. It helps clinicians in assessing people before applying medical treatments and in monitoring those who take medication that can affect clotting. Under the agreement, Abbott is the exclusive distributor of SEKISUI’s new CP3000 coagulation instrument in the United States, Europe and other regions that accept the CE Mark. The SEKISUI CP3000 system features high-quality reagents, small sample volume requirements and offers a combination of high-throughput and a compact footprint. The system connects seamlessly to Abbott’s ACCELERATOR a3600 lab automation platform and middleware solutions.
Coagulation testing has been an important focus for SEKISUI for over twenty years,” said Robert Schruender, President and Chief Operating Officer of SEKISUI Diagnostics. “We are delighted that this relationship with Abbott will bring the benefits of our system, which is a leading product in Japan, to many customers around the world.
For more information visit: http://bit.ly/cp-3000
